So I've been watching the cannabis hype cycle play out for years now, and honestly, if you're thinking about jumping into this space, you might be looking at the wrong stocks entirely.

Tilray Brands is the obvious play everyone knows about. Started as a pure-play marijuana company, then realized that wasn't working, so they went on an acquisition spree. Picked up brands across cannabis, CBD, alcohol—basically trying to become a consumer staples manager. Sounds smart on paper, right? Problem is, they've diluted the hell out of shareholders doing it. Share count up over 300% in five years, and they still can't post a sustainable profit. They're taking impairment charges everywhere. That's a red flag that the whole pivot might not be working as well as management hoped.

Here's the thing though—if you actually want exposure to a cash-flow machine that can weather these hype cycles and still fund growth, Altria is where the real opportunity sits. I know, I know, tobacco sounds boring compared to cannabis hype. But that's exactly the point.

Altria owns Marlboro, which has like 40.5% of the cigarette market. Their total cigarette market share is 45.2%. Yeah, cigarette volumes are declining, but the business still generates serious cash. And unlike Tilray, they're actually profitable. That cash funds a 6.1% dividend yield while they're simultaneously investing in next-gen products.

They've taken some L's—Juul didn't work out, early cannabis bets flopped, billions in write-offs. But here's the difference: they were strong enough to absorb those losses and keep moving. They just bought NJOY, the vape company. They're still experimenting, still trying to find the next growth driver.

The risk profile is actually better here. With Tilray, you're betting on a company that's still bleeding money to eventually find a business model that works. With Altria, you're betting on a mature, profitable business in decline—but one that's generating enough cash to fund both shareholder returns and new product development. If they ever circle back to cannabis again from a position of strength, that could be interesting.

Tilray might pop on hype, sure. But if you're actually trying to build wealth with a high-risk play, Altria gives you way better odds. Just keep watching the cigarette volumes and how they're progressing with their new initiatives. That's where the real story is.